New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
10:09 EDTWLT, KEY, STR, KBH, DHI, D, ANR, UNM, NVS, IBM, COST, N, VZ, SRC, MIDD, HMC, ALU, LVSOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Neutral from Sell at Citigroup... Costco (COST) upgraded to Market Perform from Underperform at Bernstein... D.R. Horton (DHI) upgraded to Market Perform from Underperform at Raymond James... Honda (HMC) upgraded to Outperform from Neutral at Macquarie... IBM (IBM) upgraded to Hold from Sell at Societe Generale... KB Home (KBH) upgraded to Market Perform from Underperform at Raymond James... Middleby (MIDD) upgraded to Outperform from Neutral at RW Baird.. Novartis (NVS) upgraded to Buy from Neutral at Citigroup... Platinum Group (PLG) upgraded to Outperform from Sector Perform at RBC Capital... Questar (STR) upgraded to Buy from Neutral at Citigroup... Spirit Realty (SRC) upgraded to Outperform from Market Perform at Raymond James... Unum Group (UNM) upgraded to Overweight from Equal Weight at Barclays... Verizon (VZ) upgraded to Buy from Hold at Canaccord... KeyCorp (KEY) upgraded to Outperform from Sell at CLSA... Alpha Natural (ANR) upgraded to Buy from Hold at Dahlman Rose... Walter Energy (WLT) upgraded to Buy from Hold at Dahlman Rose... NetSuite (N) upgraded to Buy from Neutral at Lazard Capital... Disney (D) upgraded to Buy from Neutral at B. Riley Caris... Las Vegas Sands (LVS) upgraded to Neutral from Sell at Compass Point.
News For ALU;COST;DHI;HMC;IBM;KBH;MIDD;NVS;STR;SRC;UNM;KEY;VZ;ANR;WLT;N;D;LVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
April 14, 2015
06:46 EDTALUAlcatel-Lucent volatility up into Nokia confirms 'advanced discussions' to buy
Subscribe for More Information
06:45 EDTHMCHonda confirms Takata airbag injured driver in March, Reuters says
Subscribe for More Information
06:31 EDTALUNokia volatility up into confirms 'advanced discussions' to buy Alcatel-Lucent
Nokia (NOK) overall option implied volatility of 42 compares to its 26-week average of 33 according to Track Data, suggesting large price movement into the company confirms 'advanced discussions' to buy Alcatel-Lucent (ALU).
05:51 EDTALUNokia confirms 'advanced discussions' to buy Alcatel-Lucent
Nokia (NOK) said in a statement, "In relation to recent media speculation Nokia and Alcatel-Lucent (ALU) confirm that they are in advanced discussions with respect to a potential full combination, which would take the form of a public exchange offer by Nokia for Alcatel-Lucent." Nokia cautioned that there "can be no certainty at this stage that these discussions will result in any agreement or transaction." The statement comes after Bloomberg reported yesterday afternoon that Nokia was in advanced talks to buy Alcatel-Lucent's wireless assets to better compete with Ericsson (ERIC) in telecommunications equipment. Shares of Nokia are down 65c to $7.65 in pre-market trading while Alcatel-Lucent is up 22c to $4.57.
05:50 EDTALUStocks with implied volatility movement; NOK ALU
Subscribe for More Information
April 13, 2015
20:16 EDTVZUSTelecom files net neutrality lawsuit against FCC
Subscribe for More Information
17:13 EDTIBMIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:12 EDTIBMIBM acquires Cleveland-based Explorys and Dallas-based Phytel
Subscribe for More Information
17:10 EDTIBMIBM establishes a Watson Health Cloud
Subscribe for More Information
16:51 EDTNVSDiplomat Pharmacy to dispense Novartis' JADENU
Diplomat Pharmacy is set to distribute JADENU, a drug recently approved by the U.S. FDA to treat patients with chronic iron overload. JADENU is a new oral formulation of EXJADE for the treatment of chronic iron overload due to blood transfusions in patients age 2 and older, and chronic iron due to NTDT in patients age 10 and older.
15:06 EDTALUNokia in advanced talks to buy Alcatel wireless assets, Bloomberg says
Subscribe for More Information
14:57 EDTALUEricsson trades higher after report of possible Alcatel-Lucent-Nokia deal
Subscribe for More Information
14:49 EDTALUAlcatel-Lucent jumps 9% after report of deal talks with Nokia
Subscribe for More Information
14:48 EDTALUNokia discussed takeover of Alcatel-Lucent, Bloomberg reports
Subscribe for More Information
14:47 EDTALUNokia in advanced talks to buy assets from Alcatel-Lucent, Bloomberg says
10:00 EDTANROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:16 EDTVZTechWeek to hold a conference
TechWeek Detroit 2015 is being held in Detroit on 4/13-19.
07:15 EDTCOSTAmerican Express shares could hit $105 in 18 months, says William Blair
William Blair analyst Robert Napoli says shares of American Express (AXP) are trading at nearly a 20% valuation discount to the S&P 500, reflecting "very high" pessimism in the name. Napoli tells investors today that other periods of "extreme pessimism" for American Express included 1998, 2001, and 2008/2009, with each proving to be a buying opportunity. He believes the current period will be no different. Napoli expects Amex shares to trend to historical valuation levels as investors look past the loss of Costco (COST) and better appreciate the company's growth opportunities. The analyst believes a stock price of around $105 is “reasonable” in about 18 months. The credit card issuer closed Friday up 43c to $79.59.
06:05 EDTANRAlpha Natural downgraded to Sell from Neutral at UBS
UBS downgraded Alpha Natural to Sell on expectations the company will become "more distressed" amid the slower recovery in coal and gas prices. The firm cut its price target for shares to 50c from $1.25.
05:21 EDTNVSNovartis to present new data that confirms high efficacy of Gilenya
Novartis announced new Gilenya analyses to be presented at the 67th American Academy of Neurology, or AAN, Annual Meeting in Washington, DC, from April 18-25, showing how Novartis is advancing methods assessing the impact of relapsing multiple sclerosis, or RMS, for patients and physicians. Data will show how adding brain shrinkage to an existing tool to assess MS disease activity will give a more precise prediction of the likelihood of future disability progression. Accurate assessment of disease activity is key to guide treatment decisions in RMS. A pooled analysis from the two-year phase III FREEDOMS and FREEDOMS II trials will further confirm Gilenya's high efficacy in previously-treated patients with highly-active RMS in achieving 'no evidence of disease activity' across four key measures: relapses, MRI lesions, brain shrinkage and disability progression. Achieving NEDA4 is especially critical for highly-active RMS patients, who are likely to lose more physical and cognitive functions over time despite being treated.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use